This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .

Post-Test - Peak Issues: Clinical Use Of Incretin-Based Therapies To Promote PPG Control In Type 2 Diabetes

INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 70% or higher.

0. Have you created an account on WebBasedCME.com? You must register and be signed in to participate and receive CME credit for this activity.

1.	A patient’s ______ level provides a record of average blood glucose levels over several months, but it is not a good indicator of glycemic variability.
A:		A1C
B:		Fasting plasma glucose (FPG)
C:		Postprandial plasma glucose (PPG)
D:		Preprandial plasma glucose (PrePG)

2.	PPG is typically measured _______ following a meal.
A:		immediately
B:		1-2 hours
C:		5-6 hours
D:		7-8 hours

3.	PPG levels have a relatively __________ influence on overall glycemic control at near normal plasma glucose levels and contribute approximately _________ when A1C is < 7.3%.
A:		small, 10%
B:		small, 30%
C:		large, 50%
D:		large, 70%

4.	The American Diabetes Association (ADA) recommends a therapeutic PPG target of _________, and the American Association of Clinical Endocrinologists (AACE) recommends _____________.
A:		< 200 mg/dL, < 180 mg/dL
B:		70-130 mg/dL, < 110 mg/dL
C:		< 180 mg/dL, < 140 mg/dL
D:		< 160 mg/dL, < 120 mg/dL

5.	A study by Bonora et al revealed that _______ of patients with type 2 diabetes experience PPG levels > 160 mg/dL.
A:		< 10%
B:		< 50%
C:		> 60%
D:		> 90%

6.	Postprandial hyperglycemia in the range of 140 to 200 mg/dL is referred to as impaired glucose tolerance (IGT) and is considered to be a prediabetic state with a risk of progression to diabetes of ________.
A:		30% over 1 year
B:		10% over 3 years
C:		30% over 3 years
D:		30% over 5 years

7.	Agents that ameliorate PPG excursions may provide cardiovascular benefits as demonstrated by their ability to _________.
A:		slow the progression of atherosclerosis
B:		increase inflammation
C:		increase blood pressure
D:		decrease A1C

8.	Postprandial hyperglycemia is a consequence of several physiologic abnormalities including insulin resistance, decreased β-cell function, and ________________.
A:		increased insulin secretion
B:		slowed gastric emptying
C:		impaired glucagon suppression
D:		decreased hepatic glucose production

9.	Which of the following is not an agent or class of agents that targets PPG levels?
A:		α-glucosidase inhibitors
B:		fast-acting insulin analogs
C:		incretin-based therapies
D:		metformin

10.	Incretin-based therapies improve PPG control by __________________.
A:		suppressing glucagon secretion
B:		accelerating gastric emptying
C:		decreasing postprandial insulin release
D:		inhibiting α-glucosidase